Floatz logo

LEVAMLODIPINE

Nonalcoholic Fatty Liver Disease (NAFLD)

Nanfang Hospital, Southern Medical UniversitySmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Nonalcoholic Fatty Liver Disease (NAFLD) cohort.

Asset / SponsorPhaseRating
URSODEOXYCHOLIC ACID
Phenomen Pharma
Phase 4BB
A THERAPEUTIC PEGYLATED FIBROBLAST GROWTH FACTOR 21 AGONIST/MIMETIC WHICH RESTORES LEPTIN RESPONSIVENESS
Bristol-Myers Squibb
Phase 2BB
AMLODIPINE
Nanfang Hospital, Southern Medical University
Phase 4BB
Micardis®
Nanfang Hospital, Southern Medical University
Phase 4B
Dr Cysteamine Bitartrate
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 2/3B

View all 11 →

Same molecule, other indications

LEVAMLODIPINE is also rated in:

HypertensionDormant
BB
Indicative ·
68 / 100
View asset →
Metabolic SyndromeDormant
BB
Indicative ·
66 / 100
View asset →
Essential HypertensionDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →